Long-term follow-up after high-dose chemotherapy and autologous stem-cell transplantation for high-grade B-cell lymphoma suggests an improved outcome for high-risk patients with respect to the age-adjusted International Prognostic Index

被引:19
作者
Bertz, H [1 ]
Zeiser, R [1 ]
Lange, W [1 ]
Fetscher, S [1 ]
Waller, CF [1 ]
Finke, J [1 ]
机构
[1] Univ Freiburg, Med Ctr, Dept Hematol & Oncol, D-79106 Freiburg, Germany
关键词
age-adjusted international prognostic index (aaIPI); autologous stem-cell transplantation (ASCT); chemosensitive disease; high-grade B-cell non-Hodgkin's lymphoma (hg B-NHL); high-dose chemotherapy (HDCT); long-term follow-up;
D O I
10.1093/annonc/mdh353
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: To evaluate the long-term benefit from high-dose chemotherapy (HDCT) with autologous stem-cell transplantation (ASCT), as part of the initial treatment for patients with chemosensitive, high-grade B non-Hodgkin's lymphoma (hg B-NHL), stratified according to the age-adjusted International Prognostic Index (aaIPI). Patients and methods: Eligible patients were 33 consecutive hg B-NHL patients responding to first-line chemotherapy and fulfilling at least one of the following criteria: stage III or IV, bulky disease, elevated lactate dehydrogenase or failure to achieve complete remission (CR). Twenty-two of 33 patients (67%) had two or three risk factors with respect to the aaIPI. All patients received HDCT with ASCT after a minimum of 6 weeks of VACOP-B standard therapy and VIP-E for mobilization. Results: After ASCT, 31 patients (94%) achieved CR. No treatment-related death occurred. The cumulative incidence of relapse at a medium follow-up of 10 years is 16% for 31 of 33 patients achieving CR. Twenty-five of 33 patients are in sustained CR with a disease-free survival of 76% [95% confidence interval (CI) 67% to 86%]. The overall survival at a median follow-up of 122 months (range 86-148) is 79% (95% Cl 68% to 89%). Conclusions: The results suggest that up-front HDCT with ASCT may improve long-term outcome in high-risk patients with chemotherapy-sensitive hg B-NHL when compared to historic populations treated solely with dose-intense chemotherapy. We observed that long-term survival of high-risk (two to three risk factors) patients is comparable to low-risk (zero to one risk factor) patients after HDCT and ASCT with a low incidence of late relapse.
引用
收藏
页码:1419 / 1424
页数:6
相关论文
共 37 条
[31]   Primary diffuse large B-cell lymphoma of the mediastinum: Outcome following high-dose chemotherapy and autologous hematopoietic cell transplantation [J].
Sehn, LH ;
Antin, JH ;
Shulman, LN ;
Mauch, P ;
Elias, A ;
Kadin, ME ;
Wheeler, C .
BLOOD, 1998, 91 (02) :717-723
[32]   International consensus conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-hodgkin's lymphomas: Report of the jury [J].
Shipp, MA ;
Abeloff, MD ;
Antman, KH ;
Carroll, G ;
Hagenbeek, A ;
Loeffler, M ;
Montserrat, E ;
Radford, JA ;
Salles, G ;
Schmitz, N ;
Symann, M ;
Armitage, JO ;
Philip, T ;
Coiffier, B .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (01) :423-429
[33]   A PREDICTIVE MODEL FOR AGGRESSIVE NON-HODGKINS-LYMPHOMA [J].
SHIPP, MA ;
HARRINGTON, DP ;
ANDERSON, JR ;
ARMITAGE, JO ;
BONADONNA, G ;
BRITTINGER, G ;
CABANILLAS, F ;
CANELLOS, GP ;
COIFFIER, B ;
CONNORS, JM ;
COWAN, RA ;
CROWTHER, D ;
DAHLBERG, S ;
ENGELHARD, M ;
FISHER, RI ;
GISSELBRECHT, C ;
HORNING, SJ ;
LEPAGE, E ;
LISTER, TA ;
MEERWALDT, JH ;
MONTSERRAT, E ;
NISSEN, NI ;
OKEN, MM ;
PETERSON, BA ;
TONDINI, C ;
VELASQUEZ, WA ;
YEAP, BY .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (14) :987-994
[34]  
SHIPP MA, 1994, BLOOD, V83, P1165
[35]   COMPARISON OF CHOP CHEMOTHERAPY WITH AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR SLOWLY RESPONDING PATIENTS WITH AGGRESSIVE NON-HODGKINS-LYMPHOMA [J].
VERDONCK, LF ;
VANPUTTEN, WLJ ;
HAGENBEEK, A ;
SCHOUTEN, HC ;
SONNEVELD, P ;
VANIMHOFF, GW ;
KLUINNELEMANS, HC ;
RAEMAEKERS, JMM ;
VANOERS, RHJ ;
HAAK, HL ;
SCHOTS, R ;
DEKKER, AW ;
DEGAST, GC ;
LOWENSBERG, B .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (16) :1045-1051
[36]   Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first-line therapy in high-risk diffuse large-cell lymphoma [J].
Vitolo, U ;
Cortellazzo, S ;
Liberati, AM ;
Freilone, R ;
Falda, M ;
Bertini, M ;
Botto, B ;
Cinieri, S ;
Levis, A ;
Locatelli, F ;
Lovisone, E ;
Marmont, F ;
Pizzuti, M ;
Rossi, A ;
Viero, P ;
Barbui, T ;
Grignani, F ;
Resegotti, L .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (02) :491-498
[37]   Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: A report from the Autologous Blood and Marrow Transplant Registry [J].
Vose, JM ;
Zhang, MJ ;
Rowlings, PA ;
Lazarus, HM ;
Bolwell, BJ ;
Freytes, CO ;
Pavlovsky, S ;
Keating, A ;
Yanes, B ;
van Besien, K ;
Armitage, JO ;
Horowitz, MM .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (02) :406-413